This is a routine shelf registration following a recent capital raise. The lack of company proceeds and recent strong financing suggest this is administrative, not a sign of immediate fundraising need. Monitor for actual issuance under the shelf, which could create dilution.
Price Chart
Executive Summary
Relmada Therapeutics filed an S-3 shelf registration to register the resale of 33,685,096 shares of common stock by selling stockholders, including 29,474,569 shares and 4,210,527 shares issuable upon exercise of pre-funded warrants, from a recent $160 million PIPE financing. The company will not receive proceeds from the resale, but the registration supports future capital raising flexibility. This follows strong clinical data for NDV-01 and a robust cash position extending into 2029.
Key Financial Metrics
Key Facts
- S-3 shelf registration filed for resale of 33,685,096 shares by selling stockholders from a March 2026 PIPE financing
- Offering includes 29,474,569 shares of common stock and 4,210,527 shares issuable upon exercise of pre-funded warrants
- Total offering value registered is $215.9 million based on a $6.41 share price
- Company will not receive any proceeds from the resale of shares by selling stockholders
- Recent $160 million PIPE financing completed in March 2026 strengthens cash position to fund operations through 2029
- Positive 12-month Phase 2 data for NDV-01 in bladder cancer showed 76% durable complete response rate
Financial Impact
The registration covers $215.9 million of shares for resale, but the company receives no proceeds. The recent $160 million PIPE financing provides significant capital.
Risk Factors
- Future issuance under the shelf could lead to shareholder dilution
- Biotech clinical development carries inherent risks of trial failure
- Pre-funded warrants could be exercised, increasing share count
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 11 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001213900-26-039967 |
| Document: ea028291501ex-fee.htm | 0001213900-26-039967 |
| Document: ea028291501ex5-1.htm | 0001213900-26-039967 |
| Document: ea028291501ex23-1.htm | 0001213900-26-039967 |
| Document: ea028291501ex23-2.htm | 0001213900-26-039967 |
| Document: ea028291501ex3-1v.htm | 0001213900-26-039967 |
| Document: ea028291501ex3-1vi.htm | 0001213900-26-039967 |
| Document: ea028291501ex3-1vii.htm | 0001213900-26-039967 |
| Document: 0001213900-26-039967-index-headers.html | 0001213900-26-039967 |
| Document: 0001213900-26-039967-index.html | 0001213900-26-039967 |
| Document: 0001213900-26-039967.txt | 0001213900-26-039967 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | Insider Cluster | $4.52 $4.12 | ▼ −8.85% | ▼ −8.63% | $3.60 (−20.35%) |
May 13, 2026 20w ago | S-3ASR | $7.42 $7.21 | ▲ +2.83% | ▲ +2.11% | $3.60 (+51.48%) |
May 12, 2026 20w ago | 8-K | $7.49 $7.03 | ▼ −6.14% | ▼ −4.98% | $3.60 (−51.94%) |
Apr 17, 2026 24w ago | DEFA14A | $7.37 $7.03 | ▼ −4.61% | ▼ −5.53% | $3.60 (−51.15%) |
Apr 3, 2026 26w ago | S-3 | $6.90 $7.38 | ▲ +6.96% | ▲ +2.82% | $3.60 (−47.83%) |
Mar 19, 2026 28w ago | Press Release | $6.07 $6.43 | ▲ +5.93% | ▲ +8.08% | $3.60 (−40.69%) |
Mar 12, 2026 29w ago | Press Release | $6.15 $6.25 | ▲ +1.63% | ▲ +2.60% | $3.60 (−41.46%) |
Mar 9, 2026 29w ago | Press Release | $7.17 $6.18 | ▼ −13.81% | ▼ −12.45% | $3.60 (−49.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access